Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy - Full Text View

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

This study is currently recruiting participants.
Verified by University of Colorado at Denver and Health Sciences Center, April 2007

Sponsored by:	University of Colorado at Denver and Health Sciences Center
Information provided by:	University of Colorado at Denver and Health Sciences Center
ClinicalTrials.gov Identifier:	NCT00452283

Purpose

There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss.

We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.

Condition

Glaucoma
Pulmonary Hypertension

Genetics Home Reference related topics:

early-onset glaucoma pulmonary arterial hypertension

MedlinePlus related topics:

Glaucoma High Blood Pressure Pulmonary Hypertension

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cross-Sectional, Defined Population, Prospective Study

Official Title:	The Effect of a Systemic Non-Selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.

Further study details as provided by University of Colorado at Denver and Health Sciences Center:

Estimated Enrollment:	100
Study Start Date:	March 2007

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

diagnosed with pulmonary hypertension
between the ages of 18 and 80 years
ability to undergo the various ocular exams.

Exclusion Criteria:

patients with other diseases that could affect the nerve fiber layer
specials populations; ie children, pregnancy, lactating females, prisoners

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452283

Contacts


Contact: Tim Byrne	720-848-5051	tim.byrne@uchsc.edu

Contact: Malik Y. Kahook, M.D.	720-848-5029	malik.kahook@uchsc.edu

Locations


United States, Colorado
	Rocky Mountain Lions Eye Institute	Recruiting
	Aurora, Colorado, United States, 80045
	Contact: Tim Byrne 720-848-5051 tim.byrne@uchsc.edu
	Contact: Malik Y. Kahook, M.D. 720-848-5029 malik.kahook@uchsc.edu
	Principal Investigator: Malik Y. Kahook, M.D.
	Sub-Investigator: Naresh Mandava, M.D.
	Sub-Investigator: David B. Badesch, M.D.
	Sub-Investigator: Douglas L. MacKenzie, M.D.

Sponsors and Collaborators

University of Colorado at Denver and Health Sciences Center

Investigators


Principal Investigator:	Malik Y. Kahook, M.D.	University of Colorado School of Medicine

More Information

Study ID Numbers:	myk06-0792
First Received:	March 23, 2007
Last Updated:	April 6, 2007
ClinicalTrials.gov Identifier:	NCT00452283
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Respiratory Tract Diseases

Glaucoma

Hypertension, Pulmonary

Lung Diseases

Eye Diseases

Vascular Diseases

Ocular Hypertension

Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 20, 2008